How To Naturally Reverse Psoriasis

Get Rid of Psoriasis and Improve Skin Health

There is a lot of bunk info out there about psoriasis and how to treat it, so I want to effectively and scientifically tackle this autoimmune disorder. 

 
 

Basics

 
 

Psoriasis is a chronic inflammatory skin disorder that affects 1 to 3 percent worldwide, 3.2% of the US population (8 million Americans). R R

The most common form is plaque psoriasis (psoriasis vulgaris), which accounts for the majority of cases. R

Psoriasis is characterized by well-circumscribed, erythematous plaques with scale that represent a response to an infiltration of inflammatory T-cells producing disease-stimulating cytokines in skin lesions. R

Symptoms

The symptoms of psoriasis are:

  • patches of thick, red skin R
  • skin inflammation R
  • silvery scales R
  • itching R
  • pain R

These symptoms most commonly affect the elbows, knees, scalp, lower back, face, palms, soles of the feet, nails, and soft tissues. R

Depression, anxiety, eating disorders, schizophrenia, sexual disorders, sleep disroders, samatoform disorders, substance abuse/dependence, and bipolar disorder are all commonly linked to psoriasis. R R

Psoriasis is also associated with:

  • Autism Spectrum Disorders R
  • Bechet's Disease R
  • Coronary heart Disease R
  • Diabetes R
  • Non-Alcoholic Fatty Liver Disease R
  • Histamine intolerance R
  • Hypertriglycerdemia R
  • Hyperuricemia R
  • Hypertension R
  • Sleep Disorders R

Mircobiome

 
 

Microbiome of the Skin

The microbiome diversity of the skin appears to be less in psoriasis patients. R

There is a high amount of Firmicutes and Actinobacteria on the skin of psoriasis patients, but a lower amount of Proteobacteria and Bacteriodetes. R

Microbiome of the Gut

Psoriasis can be exacerbated by Staphylococcus aureus and fungi like Candida albicans and Malassezia. R

Psoriatic arthritis is similar to the profile commonly observed in the gut of inflammatory bowel disease patients. R

This possibly suggests a decrease of Faecalibacterium prausnitzii and increase of E. coli. R

Gut dysbiosis in psoriatic arthritis has been shown to correlate to an increase of secretory IgA (sIgA) levels and a decrease of receptor activator of nuclear factor kappa-B ligand (RANK-L) levels within the gut luminal content. R

Intestinal Permeability

Toxic-irritative pollutants can cause problems with the gut in patients with skin disorders.R

Serum histamine levels rise when they are exposed to lactose, sucrose, tyramine, serotonine or phenylethylamine. R

This is a very common problem seen in dysbiotic patients. R

Alcohol and other toxins increased intestinal permeability, histamine release and impairment of liver detox functions. R

Psoriasis patients may have a problem in MAO, DAO, and NMT (being inhibited). R

 
 

Biomarkers and Tests

There are the biomarkers commonly found in psoriasis:

  • C4a R
  • alpha-MSH R R R
  • IL-1ß
  • IL-4 R
  • IL-6 R
  • IL-8 R
  • IL-10 R
  • IL-12 R
  • IL-17 R
  • IL-23 R
  • IL-27 R
  • TNF-a R
  • Vitamin A (Retinol) R
  • Vitamin D R R
  • Homocysteine R R R
  • Folate R
  • Uric Acid R
  • Selenium R
  • Prostaglandin E2 R
  • C-Reactive Protein R
  • H. Pylori Infection R
  • CRH R
  • Prolactin R
  • VEGF R

Here are the blood tests you can do to check for these levels.

Treatment

 
 

Actions To Take

Get more sun exposure (UVB inhibits IL-17/TNF-α-induced IL-6, IL-8, and CXCL-1 production and decreases the expression of IL-17 receptors on fibroblasts through TGF-β1/Smad3 signaling pathway) R

Decrease/Deactivate/Inhibit:

  • Alpha-MSH (sun will increase this, so increase it if you have an infection like Candida , Streptococcus, E. coli) R
  • Anxiety R
  • AP-1 R R
  • C4a
  • Homocysteine
  • IFN-gamma R
  • IL-1b
  • IL-6
  • IL-8
  • IL-23
  • Nerve Growth Factor R R
  • NF-kB R
  • Prolactin
  • Prostaglandin E2 
  • mTOR R R R
  • Stress R
  • TNF-a
  • VEGF

Increase/Activate:

Also, fix any underlying Dysbiosis and Histamine Intolerance.

Diet/Lifestyle Actions

Supplements To Take

Drugs

  • Adalimumab (for nails) R
  • Apremilast R
  • Itolizumab R
  • Liarozole (inhibits cP450) R
  • Low Dose Naltrexone (LDN) R R
  • Metformin R
  • RAMBAs R
  • Scedosporium Dehoogii R
  • Thiazolidinediones (by regulating PPAR-gamma and retinoic acid receptor activity) R

Treatments, Lotions, and Devices

  • 453nm of Blue Light R
  • Adapalene R
  • Ammonium Lactate Lotion R
  • Carbon 60 Olive Oil R
  • Ixekizumab (inhibits il-17) R
  • Low-Level Laser Therapy (LLLT) R
  • Methotrexate (better results combining it with calcium) R
  • Possibly Ammonia-Oxidizing Bacteria 
  • Tazarotene R R
  • Tretinoin R
  • Topical Corticosteroids (can have unwanted cutaneous side effects) R
  • Topical Vitamin D3 R
  • UV-B therapy (decreases MMP2) R

Other

  • BAY 11-7082 (by inhibiting NF-kB and NLRP3 ) R
  • Calcipotriol and betamethasone dipropionate R
  • Cardarine R
  • CD1a blockade R
  • Fullerene Nanomaterials (by inhibiting the allergic response) R
  • Givinostat R
  • Methylene Blue R
  • PLA2 inhibition R

Stay Away From

These have all shown to bring about psoriasis:

  • Beta-blockers R
  • Lithium R
  • Synthetic Antimmalrials R
  • NSAIDs R
  • Tetracyclines R

Avoid excessive:

  • Methionine R R R
  • Leucine (via inhibiting mTOR) R
  • Taurine (still debated) R

Mechanism Of Action

 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229247/figure/F1/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229247/figure/F1/

 

Like many other autoimmune conditions, psoriasis is mediated by T cells and dendritic cells. R

Inflammatory myeloid dendritic cells release IL-23 and IL-12 to activate IL-17-producing T cells, Th1 cells, and Th22 cells to produce abundant psoriatic cytokines IL-6, IL-17, IFN-γ, TNF, and IL-22. R R

These cytokines mediate effects on keratinocytes and mast cells to amplify psoriatic inflammation. R R

Activation of IL-17-producing T cells, leading to IL-17 release, activates CCL20, CXCL1, CXCL2, and CXCL8/IL-8 synthesis, leading to recruitment of more IL-17-producing T cells and neutrophils into the skin. R

TNF-a also stimulates VEGF and activation of NF-kB. R

Elevated levels of Nerve Growth Factor have been found in psoriasis. R

In psoriasis, skin cells have lots of Tregs but reduced Foxp3. Butyrate would help this. R R

Psoriasis patients who have itches usually have increased histamine. R

CD49a

Psoriasis is characteriszed by the accumulation of a subgroup of T cells called CD49a- and it in the afflicted skin and produces the inflammation-causing protein IL-17. R

Also, in vitiligo another kind of T cell is accumulated, called CD49a+, which recognise and are ready to kill pigment cells. R

In healthy skin, CD49a+ and CD49a cells are dormant, but quickly respond with inflammatory and cytotoxic effects when stimulated by IL-15, a protein secreted from skin cells as a rapid-response defence against microbial attack. R

Genetics

MTHFR

C677T - CC is involved with psoriasis (38.46%). R

SOD

SOD activities were significantly decreased in mild (P < 0.01), moderate (P < 0.01), severe (P < 0.01) psoriasis patients, as compared with healthy controls. R

Decreased SOD activity might be related to epidermal hyper proliferation, because the ROS are thought to induce cell proliferation in various cell systems. R

CARD

CARD14 mRNA was found to be elevated 2.7-fold in the psoriasis transcriptome (activating Bcl10 and NF-κB). R

CDKAL1

rs6908425 - CC homozygotes were significantly more common responders to anti-TNF biological drugs among Psoriasis (Psor) patients. R

NLRP3

rs3806265- increased susceptibility to psoriatic juvenile idiopathic arthritis. R

PSORS

rs3823418 - mutation in this can predict psoriasis in 68% of patients. R
rs3130457 - mutation associated with psoriasis in Chinese. R

TNFα

rs361525 - associated with psoriasis in several populations worldwide R

VDR

An increased association of the A allele for the VDR was found in patients with psoriasis. R

VEGFR

 
http://www.discoverymedicine.com/Wei-Li/2014/09/targeting-vegf-vegfr-in-the-treatment-of-psoriasis/

http://www.discoverymedicine.com/Wei-Li/2014/09/targeting-vegf-vegfr-in-the-treatment-of-psoriasis/

 

Vascular endothelial growth factor is a powerful mediator of inflammatory diseases. R

VEGF is significantly up-regulated in psoriatic skin lesions. R

More Research

  • Psoriasis and stress: NPF grantee Theoharis Theoharides discusses his psoriasis research V
  • Treating Asthma and Eczema With Plant-­Based Diets V
  • Glycine Regulates Protein Turnover by Activating Protein Kinase B/Mammalian Target of Rapamycin and by Inhibiting MuRF1 and Atrogin-1 Gene Expression in C2C12 Myoblasts. R